Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors - PubMed (original) (raw)

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors

B Roy et al. Mol Cell Biol. 1994 Dec.

Abstract

Elevated levels of mutant forms of the p53 tumor suppressor are a hallmark of many transformed cells. Multiple mechanisms such as increased stability of the protein and increased transcription of the gene can account for elevated p53 expression. Recent findings indicate that c-Myc/Max heterodimers can bind to an essential CA(C/T)GTG-containing site in the p53 promoter and elevate its expression. We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression. Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression. In examining the relative levels of c-Myc and p53 in human Burkitt's lymphomas and other B-lymphoid lines, we found that there is a correlation between the levels of c-Myc protein and p53 mRNA expression. In particular, cells that express very low levels of c-Myc protein also express low levels of p53 mRNA, while cells that express high levels of c-Myc tend to express high levels of p53 mRNA. To determine whether the p53 gene can be a target for c-Myc in vivo, we assayed the effects of antisense c-myc RNA on the levels of endogenous p53 mRNA. The results indicate that the presence of antisense c-myc RNA leads to a reduction in the levels of c-Myc protein, p53 mRNA, and expression from the p53 promoter. Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors.

PubMed Disclaimer

Cited by

CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.
Wang Z, Li Y, Yang J, Sun Y, He Y, Wang Y, Liang Y, Chen X, Chen T, Han D, Zhang N, Chen B, Zhao W, Wang L, Luo D, Yang Q. Wang Z, et al. Adv Sci (Weinh). 2024 Sep;11(34):e2404628. doi: 10.1002/advs.202404628. Epub 2024 Jul 9. Adv Sci (Weinh). 2024. PMID: 38981022 Free PMC article.
Activation of p53-regulated pro-survival signals and hypoxia-independent mitochondrial targeting of TIGAR by human papillomavirus E6 oncoproteins.
Yapindi L, Bowley T, Kurtaneck N, Bergeson RL, James K, Wilbourne J, Harrod CK, Hernandez BY, Emerling BM, Yates C, Harrod R. Yapindi L, et al. Virology. 2023 Aug;585:1-20. doi: 10.1016/j.virol.2023.05.004. Epub 2023 May 22. Virology. 2023. PMID: 37257253 Free PMC article.
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53.
Brown DW, Beatty PH, Lewis JD. Brown DW, et al. Cancers (Basel). 2022 Oct 22;14(21):5176. doi: 10.3390/cancers14215176. Cancers (Basel). 2022. PMID: 36358595 Free PMC article. Review.
MicroRNA-101a-3p mimic ameliorates spinal cord ischemia/reperfusion injury.
Zhang ZL, Wang D, Chen FS. Zhang ZL, et al. Neural Regen Res. 2022 Sep;17(9):2022-2028. doi: 10.4103/1673-5374.335164. Neural Regen Res. 2022. PMID: 35142692 Free PMC article.
Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH. Hsin IL, et al. Cells. 2021 Oct 27;10(11):2916. doi: 10.3390/cells10112916. Cells. 2021. PMID: 34831139 Free PMC article.

References

1. Oncogene. 1990 Aug;5(8):1187-93 - PubMed
1. Science. 1990 Aug 31;249(4972):1046-9 - PubMed
1. Science. 1990 Aug 31;249(4972):1049-51 - PubMed
1. Mol Cell Biol. 1990 Nov;10(11):5914-20 - PubMed
1. EMBO J. 1990 Dec;9(12):3913-22 - PubMed

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors - PubMed (original) (raw)